Neurocrine Biosciences, Inc. (NBIX)

Neurocrine Biosciences' stock has experienced several notable events in the past six months. The company reported strong Q3 2025 earnings with total net product sales reaching $790 million, marking a 28% year-over-year growth and 16% sequential growth from Q2 2025. Neurocrine Biosciences shares have gained 7.3% over the last six months and reached an all-time high closing price of $155.63 on December 10, 2025. Short interest in the stock recently decreased by 13.92%, suggesting an improvement in investor sentiment. The initiation of a Phase 2 clinical study for NBI-1065890 in adults with tardive dyskinesia was met with a mild negative market reaction, and there have been recent insider selling activities in early February 2026. The company's Q4 2025 earnings are anticipated to be reported on February 11, 2026, with analysts projecting increases in both EPS and revenue.

Demand for Neurocrine Biosciences' products has demonstrated robust patient demand and consistent double-digit sales growth. CRENESSITY has also shown strong early adoption and persistency rates. While the company's Q1 2025 report noted some seasonal variations, the overall trend indicates strong and sustained demand for its products. The company is actively expanding its sales force to further enhance market penetration.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, neuroendocrine, and neuropsychiatric disorders. The company's major marketed products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease, ALKINDI and Efmody capsules for adrenal insufficiency, Orilissa tablets for endometriosis, Oriahnn capsules for uterine fibroids, and CRENESSITY for classic congenital adrenal hyperplasia. The company also maintains a robust pipeline with promising candidates for conditions such as schizophrenia and major depressive disorder.

Headquartered in San Diego, California, Neurocrine Biosciences discovers, develops, and markets its pharmaceuticals in the United States and internationally. The company conducts clinical trials across North America, Europe, and Asia, and utilizes strategic partnerships to expand its global reach and commercialization agreements in various jurisdictions.

Neurocrine Biosciences generally maintains a positive brand reputation, particularly within the scientific and investment communities. Analyst sentiment is overwhelmingly positive, with the company receiving a consensus rating of "Moderate Buy" from numerous analysts. The company is recognized as a leader in neuroscience, driven by its dedication to discovering and developing treatments for serious brain and hormone disorders.

The ownership structure of Neurocrine Biosciences is primarily institutional, with approximately 56.01% of the company's stock held by institutional investors. Insiders own about 1.10%, while public companies and individual investors account for 42.89% of the ownership. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc, Dodge & Cox, Jpmorgan Chase & Co, and State Street Corp.